This week, we will discuss the CREDENCE trial, simply the most important nephrology trial in a generation.
Background
Atrosentan makes a return visit to NephJC, but now it goes beyond changes in proteinuria and shows improved kidney outcomes. Is it enough to overcome the fluid complications?
Background
This week, we will discuss a risk score which helps to prognosticate the most common glomerular disease. Not only is IgA most common - it is quite heterogeneous, which makes the problem of who should get treated quite difficult.
Background
They always said not to correct hypernatremia faster than 0.5 mmol/L/hour but what do they know and who are they anyways? New data questions this ancient dogma.
Background
This week, we will discuss the CREDENCE trial, simply the most important nephrology trial in a generation.